Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 8, 2014, Pages 1534-1543

  Yoon, Hai Jeon ^a,e   Kang, Keon Wook ^a,c   Chun, In Kook ^a,f   Cho, Nariya ^a   Im, Seock Ah ^a   Jeong, Sunjoo ^d   Lee, Song ^a   Jung, Kyeong Cheon ^a   Lee, Yun Sang ^a,b   Jeong, Jae Min ^a,c   Lee, Dong Soo ^a,c   Chung, June Key ^a,c   Moon, Woo Kyung ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Dankook University   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f Kangwon National University College of Medicine   (South Korea)

Author keywords

Arginine glycine aspartic acid (RGD); Estrogen receptor (ER); Fluorodeoxyglucose (FDG); Human epidermal growth factor receptor 2 (HER2); Positron emission tomography (PET); Progesterone receptor (PR)

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID GA68; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 68GA-1,4,7-TRIAZACYCLONONANE-1,4-7-TRIACETIC ACID-ISOTHIOCYANATOBENZYL-C(ARG-GLY-ASP-TYR-LYS); COORDINATION COMPOUND; ERBB2 PROTEIN, HUMAN; OLIGOPEPTIDE; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATIONAL STUDY; DIAGNOSTIC IMAGING; EVALUATION STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PET-CT SCANNER; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GENETICS; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COORDINATION COMPLEXES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84905565621     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2744-4     Document Type: Article

References (42)

1. Allred D, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68. (Pubitemid 28144151)
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502. (Pubitemid 43854964)
3. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-8.
4. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
5. Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714-21. (Pubitemid 350086472)
6. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009;27:3020-6.
7. Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin αvβ3 expression. Theranostics 2011;1:48-57.
8. Weis SM, Cheresh DA. αv Integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 2011;1:a006478.
9. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
10. Kim JH, Lee JS, Kang KW, Lee HY, Han SW, Kim TY, et al. Wholebody distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm 2012;27:65-71.
11. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
12. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res 2006;12:3942-9. (Pubitemid 44078079)
13. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, et al. [18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6610- 6.
14. Kim YH, Jeon J, Hong SH, RhimWK, Lee YS, Youn H, et al. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 2011;7:2052-60.
15. Zhu A, Shim H. Current molecular imaging positron emitting radiotracers in oncology. Nucl Med Mol Imaging 2011;45:1-14.
16. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
17. Brooks PC, Clark R, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
18. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270:1500-2. (Pubitemid 3005294)
19. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25. (Pubitemid 36929717)
20. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001;28:27-32. (Pubitemid 33065107)
21. Yen L, Benlimame N, Nie Z-R, Xiao D, Wang T, Al Moustafa A-E, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002;13:4029-44. (Pubitemid 35398568)
22. Petit A, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30. (Pubitemid 27527914)
23. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 1999;277:H2205-11. (Pubitemid 30048139)
24. Vameşu S. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom J Morphol Embryol 2007;48:121-9.
25. Ellis C, Dyson M, Stephenson T, Maltby E. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 2005;58:710-4. (Pubitemid 40956824)
26. Ellis I, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000;53:890-2.
27. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, et al. Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 2009;11:861-70.
28. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008;38:250-8. (Pubitemid 351583988)
29. Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med 2012;26:175-83.
30. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer:molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010;36:206-15.
31. Groheux D, Giacchetti S, Moretti J-L, Porcher R, EspiéM, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38:426-35.
32. Koolen B, Vrancken Peeters MJ, Wesseling J, Lips E, Vogel W, Aukema T, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2012;39:1830-8.
33. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecularmechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-33. (Pubitemid 351519691)
34. Guo J, Higashi K, Ueda Y, Oguchi M, Takegami T, Toga H, et al. Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med 2006;47:419-25. (Pubitemid 46768483)
35. Bos R, van der Hoeven JJ, van derWall E, van der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87. (Pubitemid 34072519)
36. CherkMH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucosemetabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006;47:1921-6. (Pubitemid 47544979)
37. Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16. (Pubitemid 32104770)
38. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester H-J, et al. Comparison of integrin á vâ 3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008;49:22-9.
39. Linderholm B, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009;20:1639-46.
40. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42.
41. Gerber B, Loibl S, Eidtmann H, RezaiM, Fasching P, Tesch H, et al. Neoadjuvant bevacizumab and anthracycline - taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013;24:2978- 84.
42. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641-6. (Pubitemid 36025945)